AN2 Therapeutics

an2therapeutics.com

an2therapeutics.com • HQ: Menlo Park, United States • Venture - Series Unknown 2026 • 51-200 employees • NASDAQ: ANTX

HQ: Menlo Park, United States • Venture - Series Unknown 2026 • 51-200 employees • NASDAQ: ANTX

Actively hiring

Health Care

Biotechnology

Infectious Disease Therapeutics

As featured in

SeekingAlpha

Morningstar

Overview

News

Salaries

Products

People

Growth

Offices

Financials

Overview

AN2 Therapeutics develops breakthrough medicines through our boron chemistry platform, advancing therapies for infectious diseases and cancer worldwide.

News

News seekingalpha.com 12 days ago

AN2 Therapeutics: A Failed Drug Could Become A Major Value Driver Read more

Report

Blog 17 days ago

AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)

MENLO PARK, Calif. -(BUSINESS WIRE)-Sep. 16, 2026- AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducem

Report

Blog 2 months ago

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

Abstracts highlight epetraborole's potential beneficial effects on hematological profile across clinical and nonclinical studies MENLO PARK, Calif. -(BUSINESS WIRE)-Aug. 31, 2026- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical c

Report

Blog 2 months ago

AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer

Dr. Trenor brings more than two decades of clinical, translational and drug development leadership experience advancing innovative therapies across rare diseases, hematology and oncology MENLO PARK, Calif. -(BUSINESS WIRE)-Aug. 24, 2026- AN2 Therapeutics,

Report

Blog 2 months ago

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

Expanding Phase 2 study start-up activities to support global trial of oral epetraborole in polycythemia vera Enrollment ongoing in Phase 2 investigator-initiated trial of epetraborole for M. abscessus lung disease Positive non-human primate efficacy and

Report

Blog 4 months ago

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease

Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humans Phase 1 First-In-Human (FIH) study showed favorable safety and tolerability

Report

News morningstar.com 4 months ago

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease Read more

Report

Blog 5 months ago

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

MENLO PARK, Calif. -(BUSINESS WIRE)-May 21, 2026- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairm

Report

Blog 5 months ago

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

Oral epetraborole program in polycythemia vera advancing toward Phase 2 Phase 2 investigator-initiated trial with epetraborole for M. abscessus lung disease underway Data expected in 2Q/2026 from two studies of oral AN2-502998, under development for chron

Report

Blog 5 months ago

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

MENLO PARK, Calif. -(BUSINESS WIRE)-May 7, 2026- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairma

Report

Show more news